CivicaScript® Launches Low-Cost Multiple Sclerosis Treatment to Increase Patient Access, Create Significant Savings

Generic dimethyl fumarate delayed-release capsules are 2^nd launch in 3 months

Average savings of $4,300/month compared with other generic versions

LEHI, Utah, June 24, 2025 /PRNewswire/ -- CivicaScript^®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of dimethyl fumarate delayed-release capsules. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

CivicaScript will offer dimethyl fumarate 240 mg capsules for sale to pharmacies for $47 per bottle of 60 capsules – typically a month's supply. CivicaScript recommends that pharmacies charge patients no more than $68 per bottle (CivicaScript's maximum retail price, or MaxRP ^TM).

CivicaScript's MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label. CivicaScript will offer the 120 mg and 240 mg strengths of dimethyl fumarate capsules for sale.

CivicaScript's MaxRP for dimethyl fumarate is about $4,300 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies.¹ It could significantly reduce patients' out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines' price.

"Today's launch is yet another step in our journey to make necessary medications more affordable for the patients who need them," said CivicaScript President Brent J. Eberle. "We're bringing transparency and affordability to the generic drug market in a sustainable way – saving money for patients and payers and making medicines more accessible."

The launch comes on the heels of a report in The New England Journal of Medicine Catalyst that CivicaScript's abiraterone saved consumers 64% and payers 92% when they switched from other versions of the same drug.

CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript's business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient.

Dimethyl fumarate was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.

While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place.

About CivicaScript
CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A nonprofit company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit our website. CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency.

About dimethyl fumarate
For full prescribing information and patient information, including important warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

MEDIA CONTACT:
Liz Power
[email protected]
+1 860 501 3849

¹ Compared with 2021 average reimbursement rate for all strengths of Dimethyl Fumarate.  See Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers, Federal Trade Commission Second Interim Staff Report, January 2025, at Fig. A2, Table A (pg. 34), available at  https://www.ftc.gov/system/files/ftc_gov/pdf/PBM-6b-Second-Interim-Staff-Report.pdf

SOURCE CivicaScript